Polaris Genomics utilizes genomic biomarkers and machine learning to develop the ADAPT Neuropsychiatric Biomarker Discovery Platform™, which enables researchers to create diagnostics and therapeutics for mental health conditions. This approach enhances the accuracy and efficacy of treatments by providing objective biological insights, ultimately reducing the time and cost associated with clinical trials.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing and treating mental health conditions often lack objective biological insights, leading to inaccuracies and inefficiencies in clinical trials and treatment selection. The absence of reliable biomarkers makes it difficult to develop targeted therapeutics and personalized treatment plans for neuropsychiatric disorders.
Solution
Polaris Genomics offers the ADAPT Neuropsychiatric Biomarker Discovery Platform™, which leverages genomic biomarkers and machine learning to bring biological clarity to mental health research and clinical practice. The platform uses a targeted neuropsychiatric gene panel, combined with a deep analytics engine and data repository, to identify biomarker signatures from blood samples. This approach enables the development of objective diagnostics and therapeutics, facilitating individualized treatments based on the underlying biology of mental health conditions. By focusing on biomarkers, Polaris Genomics aims to improve the accuracy and efficacy of treatments, reduce the time and cost associated with clinical trials, and accelerate the development of novel drug targets.
Target Audience
Polaris Genomics serves pharmaceutical companies developing neuropsychiatric drugs, clinical researchers, and healthcare providers seeking objective, biology-based clinical tools for advancing mental health diagnostics and treatment.
Features
- Targeted neuropsychiatric gene panel for comprehensive genomic analysis
- AI-powered analytics engine for biomarker discovery and validation
- RNA-seq on Illumina's next-generation sequencing (NGS) platforms
- Multi-omics data integration to identify potential biomarkers
- PTS-ID™ for measuring RNA expression related to HPA axis dysregulation in PTSD
- Biomarker identification for patient selection and target enrichment in drug trials